---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006206"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:35:41.719088+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Arbutus announces multiple abstracts accepted for AASLD 2023, including late-breaking imdusiran data

## Summary
- Late-breaking poster on imdusiran (AB-729) followed by VTP-300 or placebo in chronic hepatitis B subjects.
- Poster #1459-C shows baseline HBV SNPs do not impact HBsAg reductions from imdusiran.
- Oral presentation on 48-week vebicorvir + imdusiran + NrtI combination in eAg-negative CHB (Nov 12).
- Preclinical data on oral small-molecule liver-tropic PD-L1 inhibitor for HCC (Nov 13).

## SEC filing metadata
- accession: 0001171843-23-006206
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323006206/0001171843-23-006206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323006206/f8k_101123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006206
- JSON: https://secwatch.observer/filing/0001171843-23-006206.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.